Skip to main content
Premium Trial:

Request an Annual Quote

T-Cure Bioscience, Atlas Antibodies Strike Deal to Advance CDx for T-Cell Receptor Therapy Trial

NEW YORK – T-Cure Bioscience on Tuesday said it will collaborate with Atlas Antibodies to develop a companion diagnostic that will identify patients with KK-LC-1-expressing tumors who may be eligible to enroll in studies exploring the activity of its investigational autologous T-cell receptor therapy.

Under the terms of the deal, Atlas, a Swedish firm that sells PrecisA monoclonal antibodies, will supply CT83, a Kita-Kyushu lung cancer antigen 1 (KK-LC-1) antibody, that T-Cure will use to develop the companion diagnostic. The test will be used to identify patients whose tumors express KK-LC-1 and may respond well to TCR therapies targeting that antigen.

Los Angeles-based T-Cure is developing such a KK-LC-1-targeting TCR therapy for a range of tumors that express the antigen including gastric, triple-negative breast, cervical, and lung cancers. The company plans to use the companion diagnostic developed within this partnership to identify best responders in a trial slated to begin next year.

In addition to the KK-LC-1-targeting TCR therapy, T-Cure has a pipeline of autologous TCR therapies in clinical and preclinical development targeting HERV-E and NY-ESO-1 antigens that show up in various solid tumors. Earlier this year, the company struck up a licensing deal with Immunotech Biopharm to develop and commercialize 800TCR, an autologous kidney cancer TCR therapy targeting HERV-E antigens, in China. The company is also studying this drug with the National Heart, Lung, and Blood Institute in metastatic clear cell renal cell cancer patients in a Phase I trial.